Genelux Corporation Common Stock

GNLXNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
2.87 USD
↘ 0.03 (1.03%)AT CLOSE (11:59 AM EDT)
3.23
↗ 0.36 (12.37%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
3.23
↗ 0.36 (12.37%)
🔴Market: CLOSED

GNLX is currently priced at $2.87. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Furthermore, GNLX is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jun 26, 2026.

Open?$2.89
High?$2.96
Low?$2.79
Prev. Close?$2.90
Volume?353.8K
Avg. Volume?171.7K
VWAP?$2.87
Rel. Volume?2.06x
Bid / Ask
Bid?$2.19 × 100
Ask?$3.57 × 100
Spread?$1.38
Midpoint?$2.88
Valuation & Ratios
Market Cap?128.7M
Shares Out?44.8M
Float?38.2M
Float %?85.3%
P/E Ratio?N/A
P/B Ratio?5.61
EPS?-$0.75
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
26
Market Cap
130.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.genelux.com
Listed
2023-01-26
Address
2625 TOWNSGATE ROAD, SUITE 230
WESTLAKE VILLAGE, CA 91361
Phone: 805-267-9889
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
48
Piotroski F-Score?0/9Weak
Altman Z-Score?-7.28Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?8.33%Elevated
Short Interest?3.2M
Days to Cover?20.9
Free Float38.2M
Avg Daily Volume152.1K
Settlement Date2026-06-15
Financial Health
Current Ratio?3.68Strong
Quick Ratio?3.68Strong
Cash Ratio?1.28Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
33
5.61FAIR▾
P/S?
Peers
100
S&P
3
16,086.50HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
14,927.37HIGH▾
Returns & Efficiency
ROE?
S&P
3
-146.5%WEAK▾
ROA?
S&P
3
-103.7%WEAK▾
Cash Flow & Enterprise
FCF?$-27881000
Enterprise Value?$119.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist